AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RAPP

Ceesay Abraham sold $374K of RAPP

Ceesay Abraham (Chief Executive Officer) sold 8,210 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $45.61 ($45.56–$46.01, $0.37M total) across 2 trades on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ceesay Abraham
Published Sep 9, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RAPP
Bearish
medium confidence
Mentioned
$RAPP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RAPPBearishLow
01

Why it matters

The disclosed sale may trigger short‑term selling pressure but likely limited given the insider's remaining stake.

02

Market read

A modest insider sale that could slightly affect RAPP's stock price.

03

What to watch

CEO retains a sizable stake (458,977 shares) indicating continued confidence.

Relevance 3/10Novelty 4/10Timing: post‑market 2026‑09‑08

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$RAPPBearishMedium confidence
Context

CEO Ceesay Abraham sold 8,210 shares for $374,498 via a 10b5‑1 plan on 2026‑09‑08.

Expected impact

Potential modest downside of 1‑2% over the next few days.

Evidence & confidence

The sale amount is modest relative to holdings but is a direct insider disposition, often viewed negatively by traders.

Market effects

Sector

Limited; only affects biotech sector sentiment marginally.

Regional

None; impact confined to US biotech investors.

Global

Low; no broader market effect.

Counterpoint

What could challenge this read

The sale could be routine under a pre‑arranged plan, not indicative of fundamentals.

Key entities

  • Company
    Rapport Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker RAPP.

  • Executive
    Ceesay Abraham

    Chief Executive Officer of Rapport Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RAPP insider trading history →

Related articles

$RAPPMed

Rapport Therapeutics 3Q 2026: Revenue $0 Net loss $40.2M, EPS $(0.84) — 10-Q Summary

Rapport Therapeutics reported no revenue and a net loss of $40.2M in 3Q 2026, widening from a $26.9M loss in the prior-year quarter. Diluted EPS was $(0.84). The company began Phase 3 trials for RAP-219 in epilepsy and plans further trials in 2027. Collaboration revenue from Tenacia was $20M for the nine months. According to the company, they deferred one program and prioritized another.

tradingview.com
$RAPPHighAI 9/10

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label

SEC EDGAR 8-K
$RAPPMedAI 9/10

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

Rapport Therapeutics (RAPP) closed public offerings of 9.76M shares of common stock at $21.00 per share, $172.5M in convertible notes, and a concurrent private placement of 1.43M shares. Total net proceeds are approximately $410.7M. Proceeds will fund clinical trials, R&D, and general corporate purposes. The notes have a 2.25% interest rate and mature in 2032.

finance.yahoo.com